Journal
COORDINATION CHEMISTRY REVIEWS
Volume 327, Issue -, Pages 27-34Publisher
ELSEVIER SCIENCE SA
DOI: 10.1016/j.ccr.2016.04.018
Keywords
Alzheimer's disease; Amyloid beta peptide; Blood brain barrier; Contrast agent; Magnetic resonance imaging
Categories
Funding
- Universite Paris 13
- Centre National de la Recherche Scientifique (CNRS)
Ask authors/readers for more resources
Alzheimer's disease (AD) is a neurodegenerative disease that causes progressive and irreversible loss of mental functions. There is no cure for the disease, which worsens as it progresses, and may lead to death. Amyloid beta peptides (A beta) accumulation in the brain is one of the pathological hallmarks of AD. Together with different clinical examinations, brain imaging techniques are often used to detect A beta plaques inside the brain in order to increase the reliability of the diagnostic of AD. In this review, we compare the use of magnetic resonance imaging (MRI) with other imaging techniques used for A beta detection and present the state of the art concerning the use of contrast agents for MRI proposed for detection of A beta inside the brain. Recent progress in the development of gadolinium complexes and iron oxide nanoparticles as MRI contrast agents targeted toward A beta plaques are discussed. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available